Skip to main content
Contact Us
Sign Up
Subscriber Sign In
English
日本語
navigation
Search
What We Do
Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
About Vantage
Editorial team
Products & Services
Consensus Forecasts
Pharma
EvaluatePharma
EvaluatePharma Vision
Custom Solutions
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Client Success
Customer Testimonials
Thought Leadership
English
日本語
About Us
Media Centre
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Policy & Pricing
Policy & Regulation
Pricing
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Repros Therapeutics
December 31, 2014
Pharma regulatory and development news over Christmas
September 18, 2014
“Low-T” makers escape calls for broad safety trials but the damage is done
September 04, 2014
"Low-T" panel likely to lean towards risk aversion
October 24, 2013
One month on, the Repros hype starts to unravel
September 17, 2013
Repurposed Repros faces questions over patents and data
January 07, 2010
Clinical surprises drive small cap risers
December 23, 2009
Companies hoping for a christmas cash bonus
October 01, 2009
Human Genome, OncoGenex stand out small caps so far in 2009
July 14, 2009
Pfizer spoilt for choice of oncology assets
July 06, 2009
Repros faces crunch time
June 19, 2009
Companies still desperate for a partner
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
July 31, 2019
Vantage Pharma, Biotech & Medtech Half-Year Review 2019
February 26, 2019
Vantage Pharma, Biotech and Medtech 2018 in Review
Editor's Picks
October 22, 2019
Shock revelation sees Biogen erase its aducanumab losses
October 22, 2019
Vertex’s double cystic fibrosis surprise
October 23, 2019
Bristol might play a role in front-line lung cancer after all
October 23, 2019
Bloated on arrival? Biotech's weightiest new issues
October 14, 2019
Uncovering biopharma’s hidden treasures
